Jonathan Milner

Jonathan Simon Milner founded Abcam Ltd. (United Kingdom) in 1998, where he worked as Non-Executive Deputy Chairman from 2014 to 2020 and Axol Bioscience Ltd. in 2013, where he worked as Chairman from 2013 to 2023.
Dr. Milner also founded Censo Biotechnologies Ltd. Dr. Milner also currently works at Cambridge Allergy Ltd., as Chairman from 2013, Camgene Ltd., as Director, AbShare Share Plan Ltd., as Director, The Evolution Education Trust, as Non-Executive Director, Meltwind Ltd., as Executive Director, The Natural History Museum Development Trust, as Director, PhoreMost Ltd., as Director, Healx Ltd., as Non-Executive Director, Syndicate Room Group Ltd., as Non-Executive Director from 2015, Avocet 66 Ltd., as Director from 2017, Peregrine 66 Ltd., as Director from 2017, Suntail 66 Ltd., as Director from 2017, Start Codon Ltd., as Director from 2019, Cambridge Innovation Capital Ltd, as Advisor, and Meltwind Advisory LLP, as Member.
Dr. Milner also formerly worked at Bit Bio Ltd., as Chief Executive Officer & Director in 2025, Sensiia Ltd., as Chairman, DefiniGEN Ltd., as Chairman, Revvity Discovery Ltd., as Non-Executive Director, Frontier Developments Plc, as Non-Executive Director from 2012 to 2016, GeoSpock Ltd., as Non-Executive Director, Horizon Discovery Group Ltd., as Non-Executive Director, and Repositive Ltd., as Non-Executive Director.
Dr. Milner received his undergraduate degree from the University of Bath and doctorate degree from the University of Leicester.